[Polyneuropathy and fasciitis in eosinophilia-myalgia syndrome].
Eosinophilia-Myalgia-Syndrome (EMS), a newly recognized illness, was described first in October 1989, when it formed an epidemic in the USA and later also in Europe. In the meantime, ingestion of L-tryptophan containing products has been recognized to trigger this syndrome, but the pathophysiological basics are still subject to speculation. Often starting with a flu-like period, the disease is dominated by dermatologic (fasciitis) and neurologic (neuropathy, myopathy) symptoms in the subsequent stages. Reporting on an own case and reviewing the literature, clinicopathological aspects and the problems of treatment are discussed. In contrast with the majority of published cases, which showed predominance of axonal damage, our patient displayed the clinical and electro-physiologic characteristics of demyelinating neuropathy.
Hetzel
W
W
Neurologische Abteilung, Juliusspitals Würzburg.
Dangel
P
P
Molitor
H
H
D003866:Depressive Disorder / Q000188:drug therapy; D003937:Diagnosis, Differential; D016603:Eosinophilia-Myalgia Syndrome / Q000175:diagnosis* / Q000503:physiopathology; D005208:Fasciitis / Q000175:diagnosis* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009186:Myelin Sheath / Q000502:physiology; D009460:Neurologic Examination; D010525:Peripheral Nerves / Q000503:physiopathology; D011115:Polyneuropathies / Q000175:diagnosis* / Q000503:physiopathology; D011930:Reaction Time / Q000502:physiology; D009435:Synaptic Transmission / Q000502:physiology; D014364:Tryptophan / Q000008:administration & dosage / Q000009:adverse effects
D014364:Tryptophan
Polyneuropathie und Fasziitis beim Eosinophilie-Myalgie-Syndrom (EMS).